SIR Honors Global Leaders in Interventional Radiology at 2026 Annual Meeting
The Society of Interventional Radiology (SIR) awarded its highest honor, the SIR Gold Medal, to three distinguished physicians—Thierry de Baère, MD (posthumously); Scott C. Goodwin, MD, MBA, FSIR; and Lindsay Machan, MD, FSIR—during its Annual Scientific Meeting held April 12 in Toronto. The awards recognize extraordinary service to the society and the advancement of interventional radiology (IR). The ceremony was followed by the 2026 Charles T. Dotter Lecture, delivered by Andrew Holden, MBChB, EBIR, ONZM.
“These awards celebrate exceptional leaders whose passion, ingenuity and lifelong commitment have helped define and advance the field of interventional radiology,” said SIR 2025–26 President Robert A. Lookstein, MD, FSIR. “We recognize these honorees for their transformative impact on patient care, groundbreaking research, and dedication to education and service—setting new standards of excellence and inspiring colleagues and future physicians around the world.”
Gold Medal recipients recognized for innovation and impact
Thierry Jacques de Baère, MD, was posthumously honored for his pioneering contributions to oncologic interventional radiology. As head of the interventional radiology unit at Institut Gustave Roussy Cancer Center in Villejuif, France—Europe’s largest cancer center—de Baère specialized in minimally invasive therapies for liver, lung and kidney tumors. His work included intra-arterial treatments for primary and metastatic liver cancers, as well as percutaneous ablation of liver and lung tumors. He and his team also advanced preoperative portal vein embolization techniques to promote liver hypertrophy prior to surgery.
Scott C. Goodwin, MD, MBA, FSIR, a past SIR president, was recognized for his early leadership in uterine fibroid embolization (UFE). Beginning in 1996, Goodwin and his team established the safety, efficacy and clinical indications for the procedure. He also played a key role in expanding access by training and mentoring hundreds of physicians globally. Goodwin further contributed to education as course director for SIR’s national conferences on UFE and women’s health.
Lindsay Machan, MD, FSIR, an interventional radiologist at Vancouver Hospital and associate professor at the University of British Columbia, was honored for his extensive clinical innovations. Over his career, Machan performed several first-in-human procedures, including fluoroscopically guided prostatic stents and paclitaxel-coated vascular devices. He was named an Officer of the Order of Canada in 2024 in recognition of his contributions to medicine.
Dotter Lecture highlights innovation and leadership
Following the awards presentation, Andrew Holden, MBChB, FRANZCR, EBIR, ONZM, delivered the 2026 Charles T. Dotter Lecture, one of the field’s most prestigious speaking honors.
“The Dotter Lecture [is] more than a talk. It is a recognition of those who embody Dotter’s innovation, courage, and commitment to advancing IR,” said Lookstein. “Professor Holden exemplifies the spirit of Charles Dotter: innovation grounded in purpose, technical mastery paired with curiosity, and a career dedicated not only to advancing the field, but to elevating those around him.”
Holden serves as director of the Northern Region Interventional Radiology Service at Auckland City Hospital and co-directs the Vascular Intervention Research Unit. He is also a clinical professor at the University of Auckland and has held leadership roles in international IR organizations, including past president of the Asia-Pacific Society of Cardiovascular and Interventional Radiology.
A prolific contributor to the field, Holden has authored more than 160 peer-reviewed articles, contributed to five book chapters, and delivered over 700 presentations at major scientific meetings. His clinical and research interests focus on vascular interventions, including advanced endovascular aneurysm repair and treatments for claudication and critical limb ischemia. He has participated in more than 100 medical device trials, many as principal investigator and involving first-in-human technologies.
In 2018, Holden was appointed an Officer of the New Zealand Order of Merit in recognition of his contributions to vascular and endovascular medicine.